Ejaculation is the process of releasing sperm from the body. PE, also known as rapid ejaculation, premature climax, or early ejaculation, is a condition in which a man’s or his partner’s ejaculation occurs earlier than desired during a sexual encounter. The inability to delay ejaculation for more than one minute after penetration is the most common symptom of PE. PE can be divided into two categories: lifelong (primary) and acquired (secondary) PE. PE (primary) is a condition that affects a man for the rest of his life, almost from the first sexual contact. PE is acquired (secondary) when a man who has had a normal sex life develops the ailment. Early sexual experiences, sexual abuse, poor body image, depression, anxiety, aberrant hormone levels, hereditary features, inflammation and infection of the prostate or urethra, and concern about premature ejaculation are some of the psychological and biological variables that can cause PE. Frequent launches and approvals of novel premature ejaculation treatment products is expected to drive growth of the market
Get Sample Report with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-sample/1956
A comprehensive study on the impact of the Covid-19 pandemic on the global Premature Ejaculation Treatment Market is also crafted in the report.
Due to regular launches and a healthy pipeline of novel medications for the treatment of premature ejaculation, the worldwide premature ejaculation treatment market is likely to rise significantly in the near future. Furthermore, the increased occurrence of premature ejaculation among people as a result of a sedentary lifestyle is likely to boost demand for treatment solutions and propel the market forward. For instance, in 2016, Regent Pacific Group Limited, a Hong Kong-based investment group, launched its product Fortacin in the U.K. Fortacin is a topical spray, which contains low doses of two anesthetics – lidocaine and prilocaine and is indicated for the treatment of premature ejaculation. Priligy (dapoxetine) rapidly increases synaptic levels of serotonin in the central nervous system, thus improving symptoms of PE.
Key players in the market are focusing on mergers and acquisitions, in order to launch new drugs indicated for the treatment of premature ejaculation. This is expected to aid in gaining a strong foothold in the market and also creates a lucrative opportunity for other key players to focus on and provide novel drugs for premature ejaculation treatment. For example, in 2012, Furiex Pharmaceuticals, Inc. and Menarini Group entered into strategic partnership and signed a license agreement. According to the agreement, Furiex Pharmaceuticals, Inc. licensed Menarini rights to commercialize Priligy in Europe, most of Asia, Africa, Latin America, and the Middle East.
Furthermore, in the forecast period, the increased occurrence of premature ejaculation is expected to fuel demand for premature treatment solutions. Premature ejaculation, for example, affects up to 30% of males of all ages, according to statistics published in the Arab Journal of Urology in 2013. Such high prevalence of premature ejaculation is expected to significantly increase demand for its treatment drug and drive the global premature ejaculation treatment market growth.
Want to “ahead” with your competiors request a PDF Brochure with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-pdf/1956
Key Takeaways of the Premature Ejaculation Treatment Market:
Due to frequent product launches, approvals, and rising research & development activities by key players for the development of novel products, the global premature ejaculation treatment market is predicted to grow at a CAGR of 8.7% from 2018 to 2026.
North America dominated the worldwide premature ejaculation therapy market in 2017 and is likely to continue to do so in the forecast period (2018-2026). This is related to a rise in the rate of premature ejaculation in the area. For example, according to the American Urological Association (AUA), in U.S premature ejaculation is the most common form of male sexual dysfunction, affecting about 1 in three 3 aged 18 to 59.
The Asia Pacific premature ejaculation treatment market is likely to increase significantly in the near future as key manufacturers in the region launch novel premature ejaculation treatment drugs. For example, the Menarini Group, a pharmaceutical company located in Italy, marketed Priligy (dapoxetine) in Singapore in 2013.Major players operating in the premature ejaculation treatment market are Regent Pacific Group Limited, Menarini Group, Furiex Pharmaceuticals, Inc., Absorption Pharmaceuticals, LLC, Ampio Pharmaceuticals, Inc., Aytu BioScience, NeuroHealing Pharmaceuticals Inc., and Dong-A Pharmaceutical Co., Ltd.
Reasons to Purchase this Report
• Current and future of global Premature Ejaculation Treatment market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
Table of Contents
- Research Objective and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Route of Administration
- Market Snippet, By Dosage Form
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- PEST Analysis
- Pipeline Analysis
- Product Approval
- Product Launch
- Collaboration-Acquisition
- Porter’s Five Forces Analysis
- Market Dynamics
- Global Premature Ejaculation Treatment Market, By Drug Type, 2016 – 2026 (US$ Bn)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017–2026
- Segment Trends
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- Segment Trends
- Dapoxetine
- Others
- Phosphodiesterase Type 5 (PDE5) Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- Segment Trends
- Zertane
- Others
- Topical Anesthetics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- Segment Trends
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- Introduction
- Global Premature Ejaculation Treatment Market, By Route of Administration, 2016 – 2026 (US$ Bn)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017–2026
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- Introduction
- Global Premature Ejaculation Treatment Market, Dosage Form, 2016 – 2026 (US$ Bn)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017 – 2026
- Segment Trends
- Pills
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- Spray
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- Introduction
- Global Premature Ejaculation Treatment Market, By Distribution Channel, 2016 – 2026 (US$ Bn)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017–2026
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Bn)
- Introduction
- Global Premature Ejaculation Treatment Market, By Region, 2016 – 2026 (US$ Bn)
- Introduction
- Market Share Analysis, By Region, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, For Regions, 2017–2026
- North America
- Market Size and Forecast, By Drug Type, 2016 – 2026 (US$ Bn)
- Market Size and Forecast, By Route of Administration, 2016 – 2026 (US$ Bn)
- Market Size and Forecast, By Dosage Form, 2016 – 2026 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Bn)
- Market Size and Forecast, By Country, 2016 – 2026 (US$ Bn)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Drug Type, 2016 – 2026 (US$ Bn)
- Market Size and Forecast, By Route of Administration, 2016 – 2026 (US$ Bn)
- Market Size and Forecast, By Dosage Form, 2016 – 2026 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Bn)
- Market Size and Forecast, By Country, 2016 – 2026 (US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Type, 2016 – 2026 (US$ Bn)
- Market Size and Forecast, By Route of Administration, 2016 – 2026 (US$ Bn)
- Market Size and Forecast, By Dosage Form, 2016 – 2026 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Bn)
- Market Size and Forecast, By Country, 2016 – 2026 (US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, By Drug Type, 2016 – 2026 (US$ Bn)
- Market Size and Forecast, By Route of Administration, 2016 – 2026 (US$ Bn)
- Market Size and Forecast, By Dosage Form, 2016 – 2026 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Bn)
- Market Size and Forecast, By Country, 2016 – 2026 (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Africa
- Market Size and Forecast, By Drug Type, 2016 – 2026 (US$ Bn)
- Market Size and Forecast, By Route of Administration, 2016 – 2026 (US$ Bn)
- Market Size and Forecast, By Dosage Form, 2016 – 2026 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Bn)
- Market Size and Forecast, By Country, 2016 – 2026 (US$ Bn)
- Central Africa
- South Africa
- North Africa
- Middle East
- Market Size and Forecast, By Drug Type, 2016 – 2026 (US$ Bn)
- Market Size and Forecast, By Route of Administration, 2016 – 2026 (US$ Bn)
- Market Size and Forecast, By Dosage Form, 2016 – 2026 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Bn)
- Market Size and Forecast, By Country, 2016 – 2026 (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Regent Pacific Group Limited
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Menarini Group
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Furiex Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Absorption Pharmaceuticals, LLC
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Ampio Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Aytu BioScience
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- NeuroHealing Pharmaceuticals Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Dong-A Pharmaceutical Co., Ltd.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Regent Pacific Group Limited
- Section
- References
- Research Methodology
- About us and Sales Contact
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837